Semaglutide Demonstrates Benefits Across Frailty Levels
https://jamanetwork.com/journals/jama/fullarticle/2854954
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology found.
October 2, 2026 328 1
